Lisata TherapeuticsLSTA
Recorded

Lisata Therapeutics Guggenheim 3rd Annual Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration26 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Seamus FernandezSenior Managing Director

Welcome to Guggenheim's, I guess this is our third annual Healthcare Innovation Conference here in Boston. Really pleased to be joined by Marea Therapeutics. The, I guess, active ticker for the time being is under Lisata. But really pleased to have the team here. To my immediate left is Josh Lehrer. He's CEO of Marea, President and COO of Lisata. And Ian Clements immediately to his left. He's CFO. We've asked Josh to kind of provide an overview of the company because, as a reverse merger, I think there's an opportunity to learn more. But excitingly, there were data just presented at the American Heart Association for their ANGPTL4 antibody, and I think that really is particularly exciting because there was a New England Journal of Medicine article associated with it as well. I'll turn it over to Josh to kind of kick it off.

Josh LehrerCEO

Great. Thanks, Seamus, and thanks for having us here. It's great to be here. We're not even completely through this reverse merger, and we're in the fortunate position of having two molecules that have initial clinical validation and look like drugs, both first in class. We're very excited. I'll give you a quick overview on our programs, and then we can kind of touch on the reverse merger financing. Our lead program is a first-in-class antibody directed to ANGPTL4. This is a target with very strong human genetic validation, well-understood biology. It's in the same family of targets as ApoC-III and ANGPTL3, other lipid-related targets. And we're developing this for a large group of patients who have severely elevated triglycerides, severe hypertriglyceridemia.

Josh LehrerCEO

And where we think that this could be really compelling and address an unmet need is because these patients are both at risk of pancreatitis, but also mostly have diabetes, and many have established coronary artery disease. So, we have an opportunity, we think, to have a differentiated product that can be comparable to the type of really groundbreaking efficacy on triglyceride lowering seen with the ApoC-III class, but really completely avoiding the dysglycemia and the worsening diabetes and cardiovascular risk factors, which have been seen as a class effect with the ApoC-III drugs. And the data that we'll get to that was presented at AHA goes a long way towards establishing that profile that we think could address a large group of these patients and ultimately have a significant share of what's projected to be over a $10 billion market in the U.S.

Josh LehrerCEO

Yeah. And then our second program is an endocrine program, and this is a first-in-class antibody targeting the growth hormone receptor.

Josh LehrerCEO

Investors are probably aware of the Crinetics paltusotine program that was also to address these patients. The main thing to know about this program is that the majority of patients with acromegaly require chronic lifelong medical therapy with the goal of controlling the disease and normalizing IGF-1, and most patients never achieve a normal IGF-1 level.

Josh LehrerCEO

Yeah. That's because the drugs that are in the class of paltusotine, the somatostatin receptor ligands, it's only a minority of patients who respond.

Josh LehrerCEO

About a third of patients respond. We have an opportunity with a drug that's in a different class that's already really validated by a commercial product. The target is validated, but with a much better profile, potentially. We think we could be best in class and address double the number of patients, actually, that are treated by SRLs right now, and that's a big unmet need, and it's also a big opportunity. About $1 billion total in the U.S., projections for the U.S. somatostatin receptor ligand market for acromegaly, and we think that we could address twice the number of patients of the SRL class.

Josh LehrerCEO

Great. Then on the kind of what's coming next, 2027 will be a big year for us.

Josh LehrerCEO

We'll be I mean, we can kind of get to this in more detail, but we'll have kind of an important additional clinical catalyst for both programs, and we're also working on a pipeline with next-generation programs that follow our lead program.

Seamus FernandezSenior Managing Director

Great. Maybe we can just kind of go through yesterday at AHA, you presented the TIMI 78 Data as a Late Breaker. Maybe just walk us through the key findings. I think in particular, the 40% triglyceride reduction overall, but the way triglyceride lowering actually scaled with baseline triglycerides, I think, was uniquely interesting.

Josh LehrerCEO

Yeah. I know this is a conversation with someone, it's easier to kind of- Yeah, it's easier to look at see visually than to talk about lots of numbers.

Josh LehrerCEO

But, really, the main thing we learned in this study that we didn't know before was this pretty dramatic scaling of efficacy or of triglyceride lowering with baseline, the baseline triglyceride level. We published data from a phase IIa study last year in The Lancet in patients who had lower, moderate elevations in triglycerides, mostly under 300. So, kind of what you see on the far left of this slide, and we saw about 40% lowering, and we see that again. But what's new is that we also had patients in this study that covered a wide range. And we had some patients who had severe elevations, over 500. And when we break down the participants in this study by baseline level, what was really encouraging for us is to see this really scaled efficacy.

Josh LehrerCEO

Going from about 35%, near 40%, at the high dose in patients who are under 300 milligrams per deciliter to about 45% in patients who are 300 to 500. And then, in our target patients going forward- with triglycerides over 500, we're seeing the efficacy go up to 70%, 72% at the high dose. And that is very much comparable to what's been seen in terms of change from baseline with the ApoC-III class. And the reason that's important for these patients is that to really remove the risk of pancreatitis, you want to get patients below 500.

Josh LehrerCEO

Yeah. And if you deliver this kind of mean reduction, you're going to be moving the vast majority of patients below 500, and that's translated into clinical pancreatitis benefit with the ApoC-III inhibitors.

Josh LehrerCEO

The other important result is that we saw a very clean profile.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day